Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PABPC1 | P11940 | 1/20 | 0.38 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.38 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.35 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.35 |
| ▸ | GBA1 | P04062 | 2/20 | 0.32 |
| ▸ | SHBG | P04278 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12868797 | 1.00 | PABPC1 (0.38) | PABPC1APOBEC3AAPOBEC3GTDP1CA1 | |
| SCHEMBL13295358 | 1.00 | PABPC1 (0.38) | PABPC1APOBEC3AAPOBEC3GTDP1CA1 | |
| SCHEMBL14639637 | 1.00 | PABPC1 (0.38) | PABPC1APOBEC3AAPOBEC3GTDP1CA1 | |
| SCHEMBL12868804 | 1.00 | PABPC1 (0.38) | PABPC1APOBEC3AAPOBEC3GTDP1CA1 | |
| SCHEMBL13142017 | 1.00 | PABPC1 (0.38) | PABPC1APOBEC3AAPOBEC3GTDP1CA1 | |
| SCHEMBL13295353 | 1.00 | PABPC1 (0.38) | PABPC1APOBEC3AAPOBEC3GTDP1CA1 | |
| SCHEMBL9918285 | 0.95 | TRPA1 (0.35) | PABPC1APOBEC3AAPOBEC3GTDP1CA1 | |
| SCHEMBL12418390 | 0.95 | TRPA1 (0.35) | PABPC1APOBEC3AAPOBEC3GTDP1CA1 | |
| SCHEMBL12418395 | 0.95 | TRPA1 (0.35) | PABPC1APOBEC3AAPOBEC3GTDP1CA1 | |
| SCHEMBL12418391 | 0.95 | TRPA1 (0.35) | PABPC1APOBEC3AAPOBEC3GTDP1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1341512-B1 | RHINOLOGICAL AGENTS | SYMRISE GMBH & CO KG (DE) | 2008-12-31 | — | — | EP | claimed |
| EP-1341512-A1 | RHINOLOGICAL AGENTS | HAARMANN & REIMER GMBH (DE) | 2003-09-10 | — | — | EP | claimed |
| WO-2002041861-A1 | RHINOLOGICAL AGENTS | HAARMANN & REIMER GMBH (DE) | 2002-05-30 | — | — | WO | claimed |
| US-9980964-B2 | ERK inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2018-05-29 | — | — | US | disclosed |
| US-9926312-B2 | 4-azaindole derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-03-27 | — | — | US | disclosed |
| US-9926312-B2 | 4-azaindole derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-03-27 | — | — | US | disclosed |
| US-9796700-B2 | ERK inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2017-10-24 | — | — | US | disclosed |
| US-20170210729-A1 | ERK INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2017-07-27 | — | — | US | disclosed |
| US-20170137406-A1 | ERK INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2017-05-18 | — | — | US | disclosed |
| US-9561228-B2 | ERK inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-9561228-B2 | ERK inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-20160244445-A1 | 4-Azaindole Derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-08-25 | — | — | US | disclosed |
| US-20160002176-A1 | ERK INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-01-07 | — | — | US | disclosed |
| US-20150094328-A1 | 4-Azaindole Derivatives | EISAI R&D MAN CO LTD (JP) | 2015-04-02 | — | — | US | disclosed |
| US-20110028447-A1 | INDAZOLE DERIVATIVES | PFIZER INC. | 2011-02-03 | — | — | US | disclosed |
| US-20110028447-A1 | INDAZOLE DERIVATIVES | PFIZER INC. | 2011-02-03 | — | — | US | disclosed |
| US-7732424-B2 | for reducing animal core temperatures and rate of oxygen consumption; protecting against myocardial damage during cardioplegia; cardiovascular disease, neurological disorders, ophthalmic conditions, ischemic conditions, reperfusion injury, obesity, wasting disease, and/or diabetes | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-06-08 | — | — | US | disclosed |
| EP-1341512-B1 | RHINOLOGICAL AGENTS | SYMRISE GMBH & CO KG (DE) | 2008-12-31 | — | — | EP | disclosed |
| EP-1341512-A1 | RHINOLOGICAL AGENTS | HAARMANN & REIMER GMBH (DE) | 2003-09-10 | — | — | EP | disclosed |
| WO-2002041861-A1 | RHINOLOGICAL AGENTS | HAARMANN & REIMER GMBH (DE) | 2002-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137406-A1 | ERK INHIBITORS AND USES THEREOF | MAP3K20, MAP3K1, MAPK3 | PABPC1 3783/4885APOBEC3A 4381/4885APOBEC3G 3899/4885 |
| US-20160002176-A1 | ERK INHIBITORS AND USES THEREOF | MAPK1, MAPK3, MAP4K2 | PABPC1 3724/4885APOBEC3A 4401/4885APOBEC3G 4139/4885 |
| US-20160244445-A1 | 4-Azaindole Derivatives | CHRM1, CHRM4, CHRM2 | PABPC1 3368/4885APOBEC3A 2574/4885APOBEC3G 2662/4885 |
| US-20170210729-A1 | ERK INHIBITORS AND USES THEREOF | MAP3K20, MAP3K1, MAPK3 | PABPC1 3783/4885APOBEC3A 4381/4885APOBEC3G 3899/4885 |
| US-20110028447-A1 | INDAZOLE DERIVATIVES | CNR1, CNR2, GPR119 | PABPC1 4847/4885APOBEC3A 3922/4885APOBEC3G 3913/4885 |
| US-20150094328-A1 | 4-Azaindole Derivatives | CHRM1, CHRM4, CHRM2 | PABPC1 3368/4885APOBEC3A 2574/4885APOBEC3G 2662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.